Bristol/Medarex Ipilimumab Toxicity Signals Efficacy, Investigator Says

The immune response side effects of ipilimumab serve as an efficacy signal for the melanoma therapy, according to one of the lead investigators studying the Bristol-Myers Squibb/Medarex immunotherapeutic